ReviewAnnual review of medicine2013
Toward the treatment and prevention of Alzheimer's disease: rational strategies and recent progress.
Review in Annual review of medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 112 citations in OpenAlex.
- Molecular Networks and Key Regulators Underlying Resilience of the Human Brain to Aging and Dementia.Biomolecules · 2026Article
- Syringaldehyde Ameliorates Cognitive Dysfunction in APP/PS1 Mice by Stabilizing the NLRP3 Pathway.Molecular neurobiology · 2025Article
- Evolving Insights into Prickle2 in Neurodevelopment and Neurological Disorders.Molecular neurobiology · 2025Review
- Regulation of cell distancing in peri-plaque glial nets by Plexin-B1 affects glial activation and amyloid compaction in Alzheimer's disease.Nature neuroscience · 2024Article
- Therapeutic effects of a novel synthetic α-secretase.Frontiers in aging neuroscience · 2024Article
- Exposure to Low Levels of Radiofrequency Electromagnetic Fields Emitted from Cell-phones as a Promising Treatment of Alzheimer's Disease: A Scoping Review Study.Journal of biomedical physics & engineering · 2023Article
- Differential Effects of Endocannabinoids on Amyloid-Beta Aggregation and Toxicity.International journal of molecular sciences · 2023Article
- Mechanistic considerations and biomarkers level in nickel-induced neurodegenerative diseases: An updated systematic review.IBRO neuroscience reports · 2022Review
- Neuroprotective effects of donepezil against AβEuropean journal of medical research · 2022Article
- New Multifunctional Agents for Potential Alzheimer's Disease Treatment Based on Tacrine Conjugates with 2-Arylhydrazinylidene-1,3-Diketones.Biomolecules · 2022Article
- Comparison of Cerebral Cortex Transcriptome Profiles in Ischemic Stroke and Alzheimer's Disease Models.Clinical nutrition research · 2022Article
- Full- versus Sub-Regional Quantification of Amyloid-Beta Load on Mouse Brain Sections.Journal of visualized experiments : JoVE · 2022Article
- Genetic and environmental factors in Alzheimer's and Parkinson's diseases and promising therapeutic intervention via fecal microbiota transplantation.NPJ Parkinson's disease · 2021Review
- A method for the expression of fibroblast growth factor 14 and assessment of its neuroprotective effect in an Alzheimer's disease model.Annals of translational medicine · 2021Article
- New Multifunctional Agents Based on Conjugates of 4-Amino-2,3-polymethylenequinoline and Butylated Hydroxytoluene for Alzheimer's Disease Treatment.Molecules (Basel, Switzerland) · 2020Article
- Liver Growth Factor "LGF" as a Therapeutic Agent for Alzheimer's Disease.International journal of molecular sciences · 2020Article
- Associations between vascular risk factors and subsequent Alzheimer's disease in older adults.Alzheimer's research & therapy · 2020Article
- Gold Nanoparticles Mediate Improved Detection of β-amyloid Aggregates by Fluorescence.Nanomaterials (Basel, Switzerland) · 2020Article
- Ginsenoside Rg1 ameliorates the cognitive deficits in D-galactose and AlClInternational journal of medical sciences · 2020Article
- A Novel Nanosystem Realizing Curcumin Delivery Based on FeFrontiers in bioengineering and biotechnology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Alzheimer's disease (AD) is the major cause of late-life brain failure. In the past 25 years, autosomal dominant forms of AD were found to be primariy attributable to mutations in one of two presenilins, polytopic proteins that contain the catalytic site of the γ-secretase protease that releases the amyloid beta (Aβ) peptide. Some familial AD is also due to mutations in the amyloid precursor protein (APP), but recently a mutation in APP was discovered that reduces Aβ generation and is protective against AD, further implicating amyloid metabolism. Prion-like seeding of amyloid fibrils and neurofibrillary tangles has been invoked to explain the stereotypical spread of AD within the brain. Treatment trials with anti-Aβ antibodies have shown target engagement, if not significant treatment effects. Attention is increasingly focused on presymptomatic intervention, because Aβ mismetabolism begins up to 25 years before symptoms begin. AD trials deriving from new biological information involve extraordinary international collaboration and may hold the best hope for success in the fight against AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.